Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Study on SyB L-0501 [bendamustine] in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma (Multicenter, Open-Label Study).

Trial Profile

Phase II Clinical Study on SyB L-0501 [bendamustine] in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma (Multicenter, Open-Label Study).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary)
  • Indications Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors SymBio Pharmaceuticals
  • Most Recent Events

    • 21 May 2008 The projected timeline for NDA filing is now expected to be in the 4th quarter of 2009, due to the rapid pace of patient enrollment, according to a SymBio Pharmaceuticals media release.
    • 21 May 2008 Enrollment of study patients with mantle cell lymphoma is progressing at a good pace; target numbers are expected to be reached in the near future, according to a SymBio Pharmaceuticals .
    • 21 May 2008 Enrollment of patients with non-Hodgkin's lymphoma completed ahead of the predicted 15 months and within 5 months of study start, according to a SymBio Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top